Marie Thibault

Acknowledged the tougher Q3 comp outright, added the euro assumption, and pointed to tender and access wins as the offsetting driver.

Jereme cited NPS score improvement with 15-day as sustainable. Combination of product, coverage wins with low copays, and physician education driving share gains. Goal to be market leaders in every category. Jake added Smart Basal designed for basal segment with penetration still around 20% to 25%.

Jereme explained CMS coverage approval and pricing are handled separately. Competitive bidding pricing expected to kick in 2028. L code and pathology approval drive coverage decisions. Annual pricing negotiations have been stable. Building capacity as if CMS coverage came tomorrow.

Jereme confirmed scrap related to sensor deployment needle mechanism. Expects dissipation into Q4 and largely behind them entering 2026. Underlying standard performance and costs very solid YoY. Few hundred basis points combined freight and scrap impact split roughly 50-50.

Jake confirmed RCT actively running across broad T2 non-insulin population including GLP-1 and SGLT2 users. On track to read out early next year. Multiple registries globally producing real-world evidence with phenomenal glycemic control improvements.

Jereme cited levers from sales force investment completed in 2024, AI and robotics leverage, and location strategies. Still investing >$100M in OpEx YoY. Jake noted software team efficiency gains.

Ford deferred market growth projections to the competitor and redirected to Abbott's share capture opportunity with Amulet 360 and the move of LAA into the EP business.

Ford broke down Core Lab by geography: China flat (vs -15 to -30% prior year), U.S. high single digits with 90% plus renewal rates and 55% plus new business win rates, Europe mid-to-high single digits. Expects full-year Core Lab mid-single-digit growth.

Ford said biosimilar launches leverage existing EPD infrastructure across key 15 markets. Some incremental SG&A for market education needed. Targeting autoimmune, oncology, GLP-1 with launches starting 2026.

Ford expects Aveir at ~$500M run-rate exiting year. Accounts up 50%, trained physicians up 50%, daily implants doubled. Next-gen with 25% longer battery life in development, conduction system pacing pivotal trial targeted for 2026.

Mahoney credited complex PCI, imaging and the AGENT drug-coated balloon, and named coronary IVL entry, the hypertension trial and the Penumbra close as forward catalysts.

Mike acknowledged sacral neuromodulation commercial disruption lingered longer than expected with significant turnover at manager, clinical, and territory levels. Nearly 100 new hires in various training stages.

CEO highlighted interventional oncology mid-teens growth driven by robotics portfolio and Y90. Entera acquisition extends into adjacencies with pump portfolio, getting closer to oncologists.

Flavia laid out the 2027 preliminary assumptions: competition included, stable pricing, no market acceleration, and no benefit from the remediation actions.

Eric confirmed type 2 utilization very similar to type 1 and retention slightly lower but strong and consistent with expectations. Guide assumes stable retention and utilization on portfolio basis.

Ana explained margin expansion moderated by deliberate R&D investment (10-12% of revenue), sales and marketing for type 2 and international, while G&A provides leverage.